<DOC>
	<DOCNO>NCT01618708</DOCNO>
	<brief_summary>The primary objective study demonstrate change assessment pain participant receive Synvisc-One compare control .</brief_summary>
	<brief_title>A Study Safety Effectiveness Synvisc-One® ( Hylan G-F 20 ) Patients With Primary Osteoarthritis Hip</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Hylan</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>The participant symptomatic osteoarthritis ( OA ) target joint The participant diagnosis primary OA hip Screening accord American College Rheumatology ( ACR ) Criteria The participant , female childbearing potential , must negative pregnancy test take oral contraceptive least 1 month prior treatment continue duration study ( include final study visit ) , agree use 2 form contraception ( e.g. , condoms plus spermatocide ) , otherwise females must surgically sterile , postmenopausal least 1 year The participant symptomatic OA contralateral hip Western Ontario McMaster Universities Osteoarthritis Index ( WOMAC ) A1 numerical rating scale ( NRS ) score ≥ 4 Screening ( symptomatic OA WOMAC A1 NRS score 03 contralateral hip allow ) The participant woman pregnant , lactating , unwilling use adequate contraception The participant prior viscosupplementation therapy target hip joint within 26 week Screening The participant known history hypersensitivity avian protein component hyaluronanbased injection device The participant known history hypersensitivity steroid , lidocaine , and/or acetaminophen The participant known history hypersensitivity inject contrast agent previous radiological examination ( e.g. , compute tomography [ CT ] scan , angiogram , etc . ) , know history hypersensitivity shellfish iodine , impediment hip injection procedure The participant active infection area injection site The participant major surgery , arthroplasty arthroscopy target hip low extremity within 26 week Screening , plan surgery low extremity throughout duration study infectious complication The participant use investigational drug , device biologic within 12 week Screening The participant significant medical condition Investigator feel would interfere study evaluation study participation</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>